The era of Big Data and precision medicine has revolutionized many industries, including healthcare, life sciences, higher education, and insurance. Empowered by better access to information, today’s patients are taking charge of their healthcare experience. They expect medical decisions and products to be tailored to their specific needs, so that they can live full and healthy lives. The combination of patient involvement and Big Data analysis boosts innovation, through faster drug, therapy, diagnostic test, and device-development. To fulfill these expectations, a “connected health network” must be established. CancerLinQ™ is a giant leap towards the creation of such a network, organizing the explosion of information into usable knowledge, personalized for each and every patient. In this course, leaders from the American Society of Clinical Oncology (ASCO) and its wholly-owned nonprofit subsidiary, CancerLinQ LLC, will help you understand precision medicine from its origins to its bright future, and show how Big Data has transformed the healthcare landscape.
Week 1: Understanding Precision Medicine
Week 2: Precision Medicine and Beyond
This course is hosted by openSAP but the content is created and provided to you by ASCO.
Care team members, health and policy administrators, patients, researchers and life sciences professionals
There are no prerequisites for attending this course.
If you would like to enroll for this course, there are no formal prerequisites or limitations. The course is free and open for everyone. Just register for an account on openSAP and go for the course!Enroll me now
This course was held from Feb 14, 2017 through Mar 15, 2017.
3587 learners enrolled.
This course was rated with 4.18 stars in average from 285 votes.
Find out more in the certificate guidelines.
Mr. Fitzpatrick joined ASCO in 2015. He previously served as Executive Vice President and Chief Innovation Officer of the American College of Cardiology (ACC), where he jointly led the organization’s overall financial management and operational and strategic planning.
Prior to joining the ACC, Mr. Fitzpatrick was Vice President of Business Development for Lippincott Williams & Wilkins, Managing Director of The Duke/Hewlett Packard Center for Outcomes Research, and Director of the Trauma Research Laboratory at Duke University Medical Center. He received the Smithsonian Institution/Computer World Healthcare Computing Innovation Award in 1996.
Dr. Schilsky is Senior Vice President and Chief Medical Officer (CMO) of ASCO. He assumed this newly created position with the Society in February of 2013.
Formerly Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he is a highly respected leader in the field of clinical oncology. He specializes in new drug development and treatment of gastrointestinal cancers.
Dr. Schilsky is a past president of ASCO, having served in the role during 2008-2009, and also a past chair of one of the National Cancer Institute’s Cooperative Groups, Cancer and Leukemia Group B (CALGB).
Dr. Von Roenn, an ASCO member since 1986, joined the Society professionally in 2013 as Vice President of Education, Science, and Professional Development (ES&PD). In this role, she and her staff collaborate with ASCO members and volunteers to plan, implement, and evaluate all formal US-based education activities (including MOC and CME) provided by ASCO for oncology healthcare professionals. In addition, the ES&PD department support the training and professional development of oncologists throughout the trajectory of their careers.
Dr. Von Roenn has served on the ASCO Board of Directors, the ASCO Palliative Care Task Force, the Scientific Program, Cancer Education, and Cancer Communications Committees, as well as the Cancer.Net Editorial Board and the Leadership Development Working Group. She is also a Fellow of ASCO, as well as a previous ASCO-ACS Special Award recipient.
Dr. Grubbs joined ASCO in 2015 as Vice President of the newly launched Clinical Affairs Department. Before joining ASCO, Dr. Grubbs worked as a community oncologist and managing partner at Medical Oncology Hematology Consultants, PA, in Newark, Delaware.
Dr. Grubbs is a volunteer and Principal Investigator of the Delaware Christiana Care National Cancer Institute (NCI) Community Oncology Research Program. He serves on the advisory council of the Delaware Cancer Consortium, of which he has been a member since 2003.
Dr. Miller is a board-certified medical oncologist and informaticist. As Medical Director, CancerLinQ™, he provides clinical insights and informatics expertise to staff and volunteers regarding the design, implementation, and strategy for ASCO’s Big Data technology platform/rapid learning health system for oncology. He also serves as a liaison with the Physician Advisory Committee and other volunteer committees.
Prior to joining the ASCO staff as a full-time employee, he was an active volunteer for the Society, serving in numerous capacities, including on the Board of Directors, the editorial board for the Journal of Oncology Practice, and as Editor-in-Chief of Cancer.Net. He has also served on the Quality of Care, Clinical Practice, Cancer Education, and Integrated Media and Technology committees, as well as on the Health Information Technology Workgroup. He has clinical and administrative experience in both community practice and academic medicine.
Dr. Hudis is CEO of the American Society of Clinical Oncology. Previously, he served for nearly two decades as Chief of the Breast Medicine Service and Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University.
He was Co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, a former Associate Editor of the Journal of Clinical Oncology, and President of ASCO during its 50th anniversary year, 2013-2014.